TYK Medicines FY26 H1 comprehensive loss narrows 76.4% to RMB 26.88 million

• TYK Medicines posted a total comprehensive loss of RMB 26.88 million for six months ended June 30, 2026, narrowing 76.4%.
• R&D costs rose 7% to RMB 94.94 million, while administrative expenses climbed 61.3% to RMB 62.55 million.
• Other income and gains jumped to RMB 142.34 million, driven by higher government grants and a gain on deemed disposal.
• Cash and bank balances fell 45% to RMB 201.96 million; borrowings edged down to RMB 131.1 million.
• TY-9591 won conditional NMPA marketing approval in August; commercialization targeted for H2 2026, with a China tie-up signed with Qilu.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TYK Medicines Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260911-12328942), on September 11, 2026, and is solely responsible for the information contained therein.